The Nasal Drip Interleukin - 22 Relief Of Allergic Rhinitis In Mice

Objective: To investigate the immune regulation with local application of recombinantmurine interleukin-22(rm-IL-22) to nasal cavity in murine allergic rhinitis model.Methods: Twenty-four female BALB/c mice (6-to8-week-old) were randomly dividedinto control group, model group and IL-22group. There were eight mice in each group.Model group and IL-22group were prepared to construct the allergic rhinitis model. Andmeanwhile, IL-22group was locally administered into nasal cavity with rm-IL-22beforeeach OVA challenge. First of all, we detected whether IL-22receptor1(IL-22R1)expression on the mice nasal epithelial cells by indirect immunofluorescence. To evaluatethe effects of rm-IL-22on symptoms of allergic rhinitis in mice, the number of sneezesand nasal rubs were counted after the last challenge in ten minutes. The concentration ofperipheral serum OVA-special IgE (OVA-sIgE) was measured by ELISA. The nasallavage fluid was collected and levels of interferon-γ (IFN-γ), interleukin-4(IL-4),interleukin-5(IL-5), interleukin-10(IL-10), thymic stromal lymphopoietin (TSLP) weremeasured. And eosinophil was evaluated by HE staining in local mice nasal mucosa inthree groups. Finally, SPSS17.0statistical software was used to analyze data. Values ofP<0.05were considered significant.Results: Nasal epithelial cells of mice express IL-22R1. IL-22group has fewer sneezesand nasal rubs compared to model group. The levels of IL-4, IL-5and OVA-sIgE inallergic rhinitis group were significantly lower than those of model group. There werelittle eosinophil in IL-22group. The differences were statistically significant among threegroups. However, the lever of IFN-γ, IL-10and TSLP was not statistically significantbetween two groups.Conclusions: Intranasal administration of rm-IL-22inhibits the immune response ofmurine allergic rhinitis. It may be expected to become a new method for treatment ofallergic rhinitis. Objective: To explore the expression efficiency of enhanced green fluorescent protein(EGFP) which was transduced into the nasal cavity with recombinant adeno-associatedvirus (rAAV) type1, rAAV type2and rAAV type8vectors.Method: Six female BALB/c mice (6-to8-week-old) were randomly divided into threegroups, each of two. Mouse nasal cavity was dripped by rAAV type1, type2and type8with the EGFP gene. The mice were killed after the first four weeks. Then obtaincompletely mouse nasal cavity, frozen sections after fixation and decalcification. Finally,observed EGFP expression in three groups of mouse nasal mucosa under a fluorescencemicroscope.Results: The recombinant rAAV type1with EGFP gene was successful transfected inmouse nasal epithelium. And the first four weeks were stable expressed. The other twotypes of rAAV with EGFP gene showed no expression in mouse nasal mucosa.Conclusion: The rAAV type1can successfully transfect the mouse nasal mucosalepithelial cells and stably express EGFP. It can be used as a gene therapy vectors for thenasal diseases.